House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Nephrology

Anaemia in chronic kidney disease

KDIGO · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

KDIGO’s anaemia pathway first investigates reversible causes, then separates iron and erythropoiesis treatment decisions by dialysis status and patient risks. Haemoglobin targets are intended to reduce symptoms and transfusion needs without pursuing normal haemoglobin at the expense of cardiovascular or other harms. Iron initiation, iron withholding and ESA targets are distinct decisions.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Investigate anaemia before attributing it to kidney disease

  • Test for anaemia at CKD referral, during regular follow-up and when symptoms suggest it. Initial testing includes a full blood count, reticulocytes, ferritin and transferrin saturation. Suggested minimum haemoglobin surveillance is yearly in G3, twice yearly in G4 and every 3 months in G5 or dialysis, with more frequent testing when clinically needed. [1]
  • When initial tests do not explain the anaemia, investigate other causes according to the clinical picture: blood-film and haemolysis testing, inflammation, B12/folate, liver and thyroid function, paraproteins, parathyroid hormone and occult blood loss. Do not assume every anaemia in CKD is erythropoietin deficiency. [1]
  • Consider evaluation for blood loss when iron-deficiency cause is uncertain and ferritin is below 45 ng/mL, or there is otherwise unexplained microcytosis without available ferritin or a known genetic cause. Select gastrointestinal, gynaecological or urological referral according to the suspected source. [1]

Use different iron thresholds for haemodialysis and other CKD

  • For anaemia in CKD G5 on haemodialysis, consider starting iron when BOTH ferritin is at most 500 ng/mL and TSAT is at most 30%. IV iron is suggested over oral iron, with a proactive approach to maintaining stable iron status. [1]
  • For anaemia in CKD without dialysis or on peritoneal dialysis, consider iron if ferritin is below 100 ng/mL AND TSAT below 40%, OR ferritin is 100 to below 300 ng/mL AND TSAT below 25%. Choose oral or IV treatment by severity, effectiveness, tolerance, access, cost and preference. [1]
  • It is reasonable to withhold routine iron when ferritin exceeds 700 ng/mL OR TSAT reaches at least 40%. These withholding limits are not the same as criteria for starting treatment; interpret trends and the clinical context. [1]
  • During iron treatment, check haemoglobin, ferritin and TSAT about every 3 months without dialysis or on peritoneal dialysis, and every 1–3 months on haemodialysis. Increase testing after blood loss, hospitalization, changes in erythropoiesis therapy or substantial rises in iron indices. [1]
  • Switch from oral to IV iron when an optimal oral regimen has insufficient effect after 1–3 months or is poorly tolerated. Consider temporarily suspending iron during systemic infection. Even without anaemia, profound iron deficiency with ferritin below 30 ng/mL AND TSAT below 20% may justify oral or IV treatment. [1]
  • Give IV iron only where acute hypersensitivity and hypotensive reactions can be managed, and respect the product’s maximum dose. Routine steroid or antihistamine premedication is unnecessary; a tolerated test dose does not predict absence of a later hypersensitivity reaction. [1]

Correct reversible causes and individualize ESA treatment

  • Correct iron deficiency and other treatable causes before an ESA or HIF-PHI. After correction, KDIGO suggests an ESA rather than a HIF-PHI as first-line anaemia treatment; discuss symptoms, transfusion harms and risks such as stroke, cardiovascular events and cancer. [1]
  • For CKD G5 on haemodialysis or peritoneal dialysis, the suggested ESA initiation range is haemoglobin at or below 9–10 g/dL, individualized to the patient. Without dialysis, including transplant recipients and children, select the starting threshold by symptoms and the balance of benefit against ESA and transfusion harms rather than one universal cut-off. [1]
  • In adults receiving an ESA, keep the haemoglobin target below 11.5 g/dL. Individualize maintenance goals to symptoms, quality of life and transfusion avoidance; do not automatically apply the adult numerical target to children. [1]
  • Use the lowest ESA dose that achieves treatment goals. Usually avoid dose changes more often than every 4 weeks, but reduce by 25–50% when haemoglobin rises more than 1 g/dL in 2–4 weeks after initiation. [1]
  • Check haemoglobin every 2–4 weeks after starting or changing ESA dose and at least every 3 months during maintenance. Consider dose reduction rather than interruption to avoid a rapid fall, provided haemoglobin does not exceed 11.5 g/dL. [1]
  • Consider suspending ESA during hospitalization for acute stroke, vascular-access thrombosis or thromboembolic events, with individualized reinitiation. With active or previous cancer, discuss continuation or withdrawal in light of expected outcomes, especially when cancer treatment aims at cure. [1]
  • For ESA hyporesponsiveness, identify and treat reversible causes before changing strategy. Suspected ESA-associated pure red-cell aplasia requires stopping the ESA, transfusion when appropriate and specialist haematology assessment; subsequent immunosuppressive or HIF-PHI treatment needs an individualized risk–benefit decision. [1]

Keep HIF-PHI treatment selective and monitored

  • Do not combine an ESA with a HIF-PHI. HIF-PHI initiation and maintenance thresholds are not established, but using the corresponding ESA thresholds is reasonable. Use the lowest effective dose and do not exceed the product maximum. [1]
  • Avoid HIF-PHIs in patients at increased adverse-event risk; do not use them with active malignancy, a recent cardiovascular event or recent vascular thrombosis, and they are contraindicated in pregnancy. The guideline also identifies populations with insufficient safety evidence; suitability cannot be inferred from oral administration alone. [1]
  • With HIF-PHI treatment, check haemoglobin 2–4 weeks after starting or changing dose and then every 4 weeks. Monitor thyroid function during the first 3 months of roxadustat and subsequently as indicated. Stop treatment after 3–4 months if the intended erythropoietic response has not occurred. [1]
  • Suspend HIF-PHI after cardiovascular or thromboembolic events, vascular-access thrombosis or newly diagnosed cancer. Reconsider HIF-PHI or ESA treatment only after discussing individual risks, haemoglobin, symptoms and preferences. [1]

Base transfusion on clinical need and future transplantation

  • Use red-cell transfusion within an overall treatment plan, balancing benefits and harms with the patient. Avoid it where possible in transplant candidates to reduce allosensitization. For chronic anaemia, symptoms and signs should drive decisions rather than an arbitrary haemoglobin threshold. [1]
  • Transfusion can be preferable when ESA or HIF-PHI treatment is ineffective or harmful. In acute anaemia, consider it when rapid correction is needed to stabilize haemorrhage or unstable coronary disease, or for urgent preoperative correction; transplant sensitization concerns do not remove an immediate clinical need. [1]

Limitations and use

  • This summary covers evaluation, treatment thresholds and major monitoring decisions; it does not provide individual ESA/HIF-PHI prescriptions, iron-product infusion schedules, hypersensitivity treatment algorithms or a complete adverse-risk checklist.
  • Most iron-initiation and ESA-initiation recommendations are conditional and based on very-low-certainty evidence. Patient preferences, symptoms, dialysis modality, blood loss, inflammation and transplant plans remain central.
  • Ferritin is expressed in ng/mL; haemoglobin in g/dL. Unit conversion and iron-product dosing are outside this summary.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Anaemia in chronic kidney disease

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
KDIGO
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Investigate anaemia before attributing it to kidney disease
  • Use different iron thresholds for haemodialysis and other CKD
  • Correct reversible causes and individualize ESA treatment
  • Keep HIF-PHI treatment selective and monitored
  • Base transfusion on clinical need and future transplantation
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House